Executive Vice President, Chief Development Office
He is responsible for the development and advancement of Pfizer’s pipeline of medicines in several therapeutic areas, including metabolic disease and cardiovascular risks, inflammation and immunology, neuroscience, oncology and rare disease. He serves on the Portfolio Strategy and Investment Committee, which focuses on maximizing the return on R&D investment across the Pfizer portfolio. He joined Pfizer in Sandwich, U.K. as a research scientist and conducted medicinal chemistry research in the cardiovascular, gastroenterology, sexual health, urology, and allergy and respiratory diseases. Rod is the co-inventor of Enablex™ (darifenacin) and represents Pfizer on the Board of Directors for ViiV Healthcare Limited, a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV. He graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his Ph.D. at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York, working in the area of molecular recognition with Professor W.C. Still.